Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

High-resolution and high-accuracy topographic and transcriptional maps of the nucleosome barrier.

Chen Z, Gabizon R, Brown AI, Lee A, Song A, Diaz-Celis C, Kaplan CD, Koslover EF, Yao T, Bustamante C.

Elife. 2019 Jul 31;8. pii: e48281. doi: 10.7554/eLife.48281. [Epub ahead of print]

2.

Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening.

Resnick E, Bradley A, Gan J, Douangamath A, Krojer T, Sethi R, Geurink PP, Aimon A, Amitai G, Bellini D, Bennett J, Fairhead M, Fedorov O, Gabizon R, Gan J, Guo J, Plotnikov A, Reznik N, Ruda GF, Díaz-Sáez L, Straub VM, Szommer T, Velupillai S, Zaidman D, Zhang Y, Coker AR, Dowson CG, Barr HM, Wang C, Huber KVM, Brennan PE, Ovaa H, von Delft F, London N.

J Am Chem Soc. 2019 Jun 5;141(22):8951-8968. doi: 10.1021/jacs.9b02822. Epub 2019 May 22.

3.

Mitochondrial dysfunction in preclinical genetic prion disease: A target for preventive treatment?

Keller G, Binyamin O, Frid K, Saada A, Gabizon R.

Neurobiol Dis. 2019 Apr;124:57-66. doi: 10.1016/j.nbd.2018.11.003. Epub 2018 Nov 10.

PMID:
30423473
4.

Pause sequences facilitate entry into long-lived paused states by reducing RNA polymerase transcription rates.

Gabizon R, Lee A, Vahedian-Movahed H, Ebright RH, Bustamante CJ.

Nat Commun. 2018 Jul 26;9(1):2930. doi: 10.1038/s41467-018-05344-9.

5.

Identifying therapeutic targets and treatments in model systems.

Lasmézas C, Gabizon R.

Handb Clin Neurol. 2018;153:409-418. doi: 10.1016/B978-0-444-63945-5.00022-2. Review.

PMID:
29887148
6.

Autologous neural progenitor cell transplantation into newborn mice modeling for E200K genetic prion disease delays disease progression.

Frid K, Binyamin O, Fainstein N, Keller G, Ben-Hur T, Gabizon R.

Neurobiol Aging. 2018 May;65:192-200. doi: 10.1016/j.neurobiolaging.2018.01.004. Epub 2018 Jan 31.

PMID:
29494865
7.

Full molecular trajectories of RNA polymerase at single base-pair resolution.

Righini M, Lee A, Cañari-Chumpitaz C, Lionberger T, Gabizon R, Coello Y, Tinoco I Jr, Bustamante C.

Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):1286-1291. doi: 10.1073/pnas.1719906115. Epub 2018 Jan 19.

8.

Continues administration of Nano-PSO significantly increased survival of genetic CJD mice.

Binyamin O, Keller G, Frid K, Larush L, Magdassi S, Gabizon R.

Neurobiol Dis. 2017 Dec;108:140-147. doi: 10.1016/j.nbd.2017.08.012. Epub 2017 Aug 25.

PMID:
28847567
9.

Correction: Oxidation of Helix-3 Methionines Precedes the Formation of PK Resistant PrPSc.

Canello T, Frid K, Gabizon R, Lisa S, Friedler A, Moskovitz J, Gasset M, Gabizon R.

PLoS Pathog. 2017 May 3;13(5):e1006293. doi: 10.1371/journal.ppat.1006293. eCollection 2017 May.

10.

Correction: Fatal Prion Disease in a Mouse Model of Genetic E200K Creutzfeldt-Jakob Disease.

Friedman-Levi Y, Meiner Z, Canello T, Frid K, Kovacs GG, Budka H, Avrahami D, Gabizon R.

PLoS Pathog. 2017 May 3;13(5):e1006294. doi: 10.1371/journal.ppat.1006294. eCollection 2017 May.

11.

Chronic Progressive Neurodegeneration in a Transgenic Mouse Model of Prion Disease.

Fainstein N, Dori D, Frid K, Fritz AT, Shapiro I, Gabizon R, Ben-Hur T.

Front Neurosci. 2016 Nov 11;10:510. eCollection 2016.

12.

Treatment of a multiple sclerosis animal model by a novel nanodrop formulation of a natural antioxidant.

Binyamin O, Larush L, Frid K, Keller G, Friedman-Levi Y, Ovadia H, Abramsky O, Magdassi S, Gabizon R.

Int J Nanomedicine. 2015 Nov 20;10:7165-74. doi: 10.2147/IJN.S92704. eCollection 2015. Erratum in: Int J Nanomedicine. 2018 Aug 29;13:4845.

13.

Aggregation of MBP in chronic demyelination.

Frid K, Einstein O, Friedman-Levi Y, Binyamin O, Ben-Hur T, Gabizon R.

Ann Clin Transl Neurol. 2015 Jul;2(7):711-21. doi: 10.1002/acn3.207. Epub 2015 Jun 6.

14.

Correction: PrPST, a Soluble, Protease Resistant and Truncated PrP Form Features in the Pathogenesis of a Genetic Prion Disease.

Friedman-Levi Y, Mizrahi M, Frid K, Binyamin O, Gabizon R.

PLoS One. 2015 Jul 20;10(7):e0133911. doi: 10.1371/journal.pone.0133911. eCollection 2015. No abstract available.

15.

The heat released during catalytic turnover enhances the diffusion of an enzyme.

Riedel C, Gabizon R, Wilson CA, Hamadani K, Tsekouras K, Marqusee S, Pressé S, Bustamante C.

Nature. 2015 Jan 8;517(7533):227-30. doi: 10.1038/nature14043. Epub 2014 Dec 10.

16.

Allosteric modulation of protein oligomerization: an emerging approach to drug design.

Gabizon R, Friedler A.

Front Chem. 2014 Mar 24;2:9. doi: 10.3389/fchem.2014.00009. eCollection 2014. Review.

17.

Pomegranate seed oil nanoemulsions for the prevention and treatment of neurodegenerative diseases: the case of genetic CJD.

Mizrahi M, Friedman-Levi Y, Larush L, Frid K, Binyamin O, Dori D, Fainstein N, Ovadia H, Ben-Hur T, Magdassi S, Gabizon R.

Nanomedicine. 2014 Aug;10(6):1353-63. doi: 10.1016/j.nano.2014.03.015. Epub 2014 Apr 2.

PMID:
24704590
18.

Genetic prion disease: no role for the immune system in disease pathogenesis?

Friedman-Levi Y, Binyamin O, Frid K, Ovadia H, Gabizon R.

Hum Mol Genet. 2014 Aug 1;23(15):4134-41. doi: 10.1093/hmg/ddu134. Epub 2014 Mar 25. Erratum in: Hum Mol Genet. 2014 Nov 15;23(22):6138.

PMID:
24667414
19.

Acetylation of lysine 382 and phosphorylation of serine 392 in p53 modulate the interaction between p53 and MDC1 in vitro.

Shahar OD, Gabizon R, Feine O, Alhadeff R, Ganoth A, Argaman L, Shimshoni E, Friedler A, Goldberg M.

PLoS One. 2013 Oct 23;8(10):e78472. doi: 10.1371/journal.pone.0078472. eCollection 2013.

20.

PrP(ST), a soluble, protease resistant and truncated PrP form features in the pathogenesis of a genetic prion disease.

Friedman-Levi Y, Mizrahi M, Frid K, Binyamin O, Gabizon R.

PLoS One. 2013 Jul 26;8(7):e69583. doi: 10.1371/journal.pone.0069583. Print 2013. Erratum in: PLoS One. 2015;10(7):e0133911.

21.

Monitoring the HIV-1 integrase enzymatic activity using atomic force microscopy in a 2LTR system.

Guy S, Rotem D, Hayouka Z, Gabizon R, Levin A, Zemel L, Loyter A, Porath D, Friedler A.

Chem Commun (Camb). 2013 Apr 18;49(30):3113-5. doi: 10.1039/c3cc40748a. Epub 2013 Mar 6.

PMID:
23463374
22.

Snord 3A: a molecular marker and modulator of prion disease progression.

Cohen E, Avrahami D, Frid K, Canello T, Levy Lahad E, Zeligson S, Perlberg S, Chapman J, Cohen OS, Kahana E, Lavon I, Gabizon R.

PLoS One. 2013;8(1):e54433. doi: 10.1371/journal.pone.0054433. Epub 2013 Jan 21.

23.

Multiple pathways for high voltage-activated ca(2+) influx in anterior pituitary lactotrophs and somatotrophs.

Tzour A, Sosial E, Meir T, Canello T, Naveh-Many T, Gabizon R, Nussinovitch I.

J Neuroendocrinol. 2013 Jan;25(1):76-86. doi: 10.1111/j.1365-2826.2012.02372.x.

PMID:
22882461
24.

Specific recognition of p53 tetramers by peptides derived from p53 interacting proteins.

Gabizon R, Brandt T, Sukenik S, Lahav N, Lebendiker M, Shalev DE, Veprintsev D, Friedler A.

PLoS One. 2012;7(5):e38060. doi: 10.1371/journal.pone.0038060. Epub 2012 May 31.

25.

Targeting of prion-infected lymphoid cells to the central nervous system accelerates prion infection.

Friedman-Levi Y, Hoftberger R, Budka H, Mayer-Sonnenfeld T, Abramsky O, Ovadia H, Gabizon R.

J Neuroinflammation. 2012 Mar 21;9:58. doi: 10.1186/1742-2094-9-58.

26.

Copper is toxic to PrP-ablated mice and exacerbates disease in a mouse model of E200K genetic prion disease.

Canello T, Friedman-Levi Y, Mizrahi M, Binyamin O, Cohen E, Frid K, Gabizon R.

Neurobiol Dis. 2012 Mar;45(3):1010-7. doi: 10.1016/j.nbd.2011.12.020. Epub 2011 Dec 16.

PMID:
22198568
27.

Fatal prion disease in a mouse model of genetic E200K Creutzfeldt-Jakob disease.

Friedman-Levi Y, Meiner Z, Canello T, Frid K, Kovacs GG, Budka H, Avrahami D, Gabizon R.

PLoS Pathog. 2011 Nov;7(11):e1002350. doi: 10.1371/journal.ppat.1002350. Epub 2011 Nov 3. Erratum in: PLoS Pathog. 2017 May 3;13(5):e1006294.

28.

Tau and 14-3-3 of genetic and sporadic Creutzfeldt-Jakob disease patients in Israel.

Meiner Z, Kahana E, Baitcher F, Korczyn AD, Chapman J, Cohen OS, Milo R, Aharon-Perez J, Abramsky O, Gabizon R, Rosenmann H.

J Neurol. 2011 Feb;258(2):255-62. doi: 10.1007/s00415-010-5738-6. Epub 2010 Sep 9.

PMID:
20827556
29.

The C terminus of p53 binds the N-terminal domain of MDM2.

Poyurovsky MV, Katz C, Laptenko O, Beckerman R, Lokshin M, Ahn J, Byeon IJ, Gabizon R, Mattia M, Zupnick A, Brown LM, Friedler A, Prives C.

Nat Struct Mol Biol. 2010 Aug;17(8):982-9. doi: 10.1038/nsmb.1872. Epub 2010 Jul 18. Erratum in: Nat Struct Mol Biol. 2011 Apr;18(4):516.

30.

Oxidation of Helix-3 methionines precedes the formation of PK resistant PrP.

Canello T, Frid K, Gabizon R, Lisa S, Friedler A, Moskovitz J, Gasset M, Gabizon R.

PLoS Pathog. 2010 Jul 1;6(7):e1000977. doi: 10.1371/journal.ppat.1000977. Erratum in: PLoS Pathog. 2017 May 3;13(5):e1006293.

31.

The structural intolerance of the PrP alpha-fold for polar substitution of the helix-3 methionines.

Lisa S, Meli M, Cabello G, Gabizon R, Colombo G, Gasset M.

Cell Mol Life Sci. 2010 Aug;67(16):2825-38. doi: 10.1007/s00018-010-0363-1. Epub 2010 May 9.

PMID:
20454997
32.

Age-related alterations affect the susceptibility of mice to prion infection.

Avrahami D, Gabizon R.

Neurobiol Aging. 2011 Nov;32(11):2006-15. doi: 10.1016/j.neurobiolaging.2009.12.015. Epub 2009 Dec 31.

PMID:
20045218
33.

Detection of oxidized methionine in selected proteins, cellular extracts and blood serums by novel anti-methionine sulfoxide antibodies.

Oien DB, Canello T, Gabizon R, Gasset M, Lundquist BL, Burns JM, Moskovitz J.

Arch Biochem Biophys. 2009 May 1;485(1):35-40.

34.

Methionine sulfoxides on prion protein Helix-3 switch on the alpha-fold destabilization required for conversion.

Colombo G, Meli M, Morra G, Gabizon R, Gasset M.

PLoS One. 2009;4(1):e4296. doi: 10.1371/journal.pone.0004296. Epub 2009 Jan 27.

35.

Methionine sulfoxides on PrPSc: a prion-specific covalent signature.

Canello T, Engelstein R, Moshel O, Xanthopoulos K, Juanes ME, Langeveld J, Sklaviadis T, Gasset M, Gabizon R.

Biochemistry. 2008 Aug 26;47(34):8866-73. doi: 10.1021/bi800801f. Epub 2008 Aug 5.

PMID:
18680312
36.

Induced neuroprotection independently from PrPSc accumulation in a mouse model for prion disease treated with simvastatin.

Haviv Y, Avrahami D, Ovadia H, Ben-Hur T, Gabizon R, Sharon R.

Arch Neurol. 2008 Jun;65(6):762-75. doi: 10.1001/archneur.65.6.762.

PMID:
18541796
37.

Virus-induced alterations of membrane lipids affect the incorporation of PrP Sc into cells.

Avrahami D, Dayan-Amouyal Y, Tal S, Mincberg M, Davis C, Abramsky O, Gabizon R.

J Neurosci Res. 2008 Sep;86(12):2753-62. doi: 10.1002/jnr.21720.

PMID:
18478553
38.

Chemically induced accumulation of GAGs delays PrP(Sc) clearance but prolongs prion disease incubation time.

Mayer-Sonnenfeld T, Avrahami D, Friedman-Levi Y, Gabizon R.

Cell Mol Neurobiol. 2008 Nov;28(7):1005-15. doi: 10.1007/s10571-008-9274-1. Epub 2008 Mar 19.

PMID:
18350378
39.

Cellular prion protein co-localizes with nAChR beta4 subunit in brain and gastrointestinal tract.

Petrakis S, Irinopoulou T, Panagiotidis CH, Engelstein R, Lindstrom J, Orr-Urtreger A, Gabizon R, Grigoriadis N, Sklaviadis T.

Eur J Neurosci. 2008 Feb;27(3):612-20. doi: 10.1111/j.1460-9568.2008.06037.x. Erratum in: Eur J Neurosci. 2008 Apr;27(8):2212.

PMID:
18279314
40.

Using peptides to study the interaction between the p53 tetramerization domain and HIV-1 Tat.

Gabizon R, Mor M, Rosenberg MM, Britan L, Hayouka Z, Kotler M, Shalev DE, Friedler A.

Biopolymers. 2008;90(2):105-16. doi: 10.1002/bip.20919.

PMID:
18189286
41.

Copaxone interferes with the PrP Sc-GAG interaction.

Engelstein R, Ovadia H, Gabizon R.

Eur J Neurol. 2007 Aug;14(8):877-84.

PMID:
17662008
42.

Fatal neurological disease in scrapie-infected mice induced for experimental autoimmune encephalomyelitis.

Friedman-Levi Y, Ovadia H, Hoftberger R, Einstein O, Abramsky O, Budka H, Gabizon R.

J Virol. 2007 Sep;81(18):9942-9. Epub 2007 Jul 11.

43.

Urine from scrapie-infected hamsters comprises low levels of prion infectivity.

Kariv-Inbal Z, Ben-Hur T, Grigoriadis NC, Engelstein R, Gabizon R.

Neurodegener Dis. 2006;3(3):123-8.

PMID:
16954698
44.

Prion urine comprises a glycosaminoglycan-light chain IgG complex that can be stained by Congo red.

Halimi M, Dayan-Amouyal Y, Kariv-Inbal Z, Friedman-Levi Y, Mayer-Sonnenfeld T, Gabizon R.

J Virol Methods. 2006 May;133(2):205-10. Epub 2006 Jan 4.

PMID:
16386805
45.

The metabolism of glycosaminoglycans is impaired in prion diseases.

Mayer-Sonnenfeld T, Zeigler M, Halimi M, Dayan Y, Herzog C, Lasmezas CI, Gabizon R.

Neurobiol Dis. 2005 Dec;20(3):738-43. Epub 2005 Jun 13.

PMID:
15951190
46.

Characterization of light chain immunoglobulin in urine from animals and humans infected with prion diseases.

Kariv-Inbal Z, Halimi M, Dayan Y, Engelstein R, Gabizon R.

J Neuroimmunol. 2005 May;162(1-2):12-8.

PMID:
15833355
47.

Inhibition of P53-related apoptosis had no effect on PrP(Sc) accumulation and prion disease incubation time.

Engelstein R, Grigoriadis N, Greig NH, Ovadia H, Gabizon R.

Neurobiol Dis. 2005 Mar;18(2):282-5.

PMID:
15686956
48.

PrPSc incorporation to cells requires endogenous glycosaminoglycan expression.

Hijazi N, Kariv-Inbal Z, Gasset M, Gabizon R.

J Biol Chem. 2005 Apr 29;280(17):17057-61. Epub 2005 Jan 24.

49.

Copper binding to PrPC may inhibit prion disease propagation.

Hijazi N, Shaked Y, Rosenmann H, Ben-Hur T, Gabizon R.

Brain Res. 2003 Dec 12;993(1-2):192-200.

PMID:
14642846
50.

Novel heparan mimetics potently inhibit the scrapie prion protein and its endocytosis.

Schonberger O, Horonchik L, Gabizon R, Papy-Garcia D, Barritault D, Taraboulos A.

Biochem Biophys Res Commun. 2003 Dec 12;312(2):473-9.

PMID:
14637161

Supplemental Content

Loading ...
Support Center